FHTX · CIK 1822462
What Foghorn Therapeutics Inc. told the SEC could break it.
Foghorn's disclosures center on its reliance on outside parties to do its science and on the financing to pay for it. It depends on third-party contract development, manufacturing and research organizations — some located outside the U.S., including in China — to run preclinical experiments and make its clinical product supplies, leaving it exposed to offshore vendor-availability risk. That China exposure carries a specific regulatory overlay: BIOSECURE-type legislation in Congress to limit U.S. biotechs from using equipment or services from select Chinese biotechnology companies could force it to replace those vendors and disrupt its supply chain. Underlying it all, it is a pre-revenue clinical-stage company that has only ever earned collaboration revenue (from Lilly), may never be profitable, and needs substantial additional equity, debt or partnership funding to continue.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- Legislation restricting use of select Chinese biotechnology vendors (BIOSECURE-type)medium
Congressional legislation limiting U.S. biotech companies from using equipment or services from select Chinese biotechnology companies could force Foghorn to replace China-based CDMOs/CROs, disrupting its manufacturing and research supply chain.
“legislation has been passed in Congress to limit certain U.S. biotechnology companies from using equipment or services produced or provided by select Chinese biotechnology companies”
SEC filing →As of 2026
Supplier concentration
- Reliance on third-party CDMOs/CROs, including in China, for manufacturing and researchmedium
Foghorn relies on contract development/manufacturing and research organizations — some located outside the U.S., including in China — to make its preclinical and clinical product supplies and conduct experiments, exposing it to offshore supply and vendor-availability risk.
“We currently rely on third parties to perform certain pre-clinical experiments, manufacture preclinical and clinical product supplies and to manufacture clinical supplies of our product candidates, and certain of these third parties are located outside the United States, including in China.”
Liquidity & debt
- Pre-revenue clinical-stage company dependent on financing/collaborationlow
Foghorn has never generated product revenue (only collaboration revenue from Lilly) and may never be profitable, needing substantial additional equity, debt, or collaboration funding to continue operations.
“We have never generated revenue from product sales and may never be profitable.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“On December 10, 2021, we entered into a collaboration agreement (the “Lilly Collaboration Agreement”) with Eli Lilly and Company (“Lilly”), for which we received an upfront payment of $300.0 million in January 2022”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch